Drugs / Ramucirumab
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (7) | US (FDA) | CYRAMZA | — | 2014-11-05 – 2025-04-07 | fda.gov ↗ |
| Approved | EU (EMA) | Cyramza | — | 2014-12-19 | europa.eu ↗ |
| Approved | US (FDA) | CYRAMZA | — | 2014-04-21 | fda.gov ↗ |
Trials 134 · started per year
today
US approved 2014
EU approved 2014
1
1
2
4
5
9
7
5
1
3
15
13
4
6
12
16
9
2
6
8
2
1
200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
Also used as a comparator or background therapy in 38 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 114 trials | ||||||
| Phase 1 | NCT07594548 Background | Sep 2027 → Sep 2030 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Northwestern University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06675136 Background | Oct 2025 → Jan 2029 expected | gastric adenocarcinoma, peritoneum cancer | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05365581 Background | Jun 2022 → May 2028 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05062980 Comparator | Mar 2022 → Feb 2025 | non-small cell lung carcinoma | Genprex, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT06542731 Background | Jun 2021 → Sep 2026 expected | non-small cell lung carcinoma | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04999761 Background | Jun 2021 → May 2026 overdue | alveolar soft part sarcoma, biliary tract cancer, colorectal cancer, esophageal cancer +4 | Taiho Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT04495478 Comparator | Jul 2020 → May 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03863587 Comparator | Jun → Sep 2019 | — | Shanghai Henlius Biotech | Terminated | No outcome recorded |
| Phase 1 | NCT03798626 Background | May 2019 → Mar 2023 | colorectal cancer, gastroesophageal cancer, renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03872947 Background | Apr 2019 → Jun 2026 overdue | cholangiocarcinoma, colorectal cancer, fallopian tube cancer, gastric cancer +5 | Toray Industries, Inc | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03193918 Background | Apr 2017 → Jul 2020 | gastroesophageal adenocarcinoma | Arog Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03013218 Background | Feb 2017 → Feb 2022 | metastatic malignant neoplasm, non-Hodgkin lymphoma | ALX Oncology Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02970539 Background | Dec 2016 → Mar 2019 | esophageal cancer, gastric cancer, gastroesophageal cancer | Athenex, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT01285037 Background | Sep 2009 → Jul 2017 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06771622 Background | Mar 2025 → Jan 2028 expected | — | FBD Biologics Limited | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03281369 Comparator | Oct 2017 → Oct 2025 | digestive system carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT07603856 Comparator | Dec 2026 → Jun 2030 expected | non-small cell lung carcinoma | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT07691645 Background | Sep 2026 → Aug 2029 expected | hepatocellular carcinoma | Xiang-Qian | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07546812 Background | Jul 2026 → Jan 2030 expected | Her2-receptor negative breast cancer, esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Gilead Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06904300 Comparator | Aug 2025 → Apr 2028 expected | gastric cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06680622 Background | Mar 2025 → Sep 2027 expected | gastroesophageal adenocarcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06043427 Background | Apr 2024 → Jun 2026 overdue | gastroesophageal adenocarcinoma | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 2 | NCT06251973 Background | Feb 2024 → Aug 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06038578 Background | Oct 2023 → Jun 2026 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Toray Industries, Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT05190445 Background | Nov 2021 → Feb 2023 overdue | carcinoma | Pieris Pharmaceuticals GmbH | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04267913 Comparator | Sep 2020 → Oct 2025 | squamous cell lung carcinoma | SWOG Cancer Research Network | Withdrawn | No outcome recorded |
| Phase 2 | NCT04310007 Comparator | Jul 2020 → Dec 2026 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03704077 Comparator | Oct 2019 → Feb 2022 | gastric carcinoma, gastroesophageal junction adenocarcinoma | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 2 | NCT03909334 Comparator | Jul 2019 → Dec 2026 expected | metastatic malignant neoplasm, non-small cell lung carcinoma | Xiuning Le | Active not recruiting | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT06616584 Background | May 2025 → Dec 2027 expected | non-small cell lung carcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06203600 Background | Jun 2024 → Oct 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05096663 Comparator | Mar 2022 → Jun 2027 expected | non-small cell lung carcinoma | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05002127 Background | Jan 2022 → May 2024 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | ALX Oncology Inc. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04499924 Background | Mar 2021 → Apr 2024 | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT03081143 Background | May 2017 → May 2026 | gastroesophageal cancer | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06346392 Comparator | Mar 2024 → May 2026 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06123494 Comparator | Jan 2024 → Jun 2027 expected | gastroesophageal adenocarcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT04704934 Comparator | May 2021 → Aug 2026 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Daiichi Sankyo | Active not recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 178 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ramucirumab | “Ramucirumab is a fully human immunoglobulin G1 monoclonal antibody receptor antagonist designed to block the ligand-binding site of vascular endothelial growth factor...” PMID 25787923 ↗ Mar 2015166“Immunotherapy, with agents including but not limited to ramucirumab, pembrolizumab, camrelizumab, and tislelizumab.” NCT07691645 ↗ “Biological/Vaccine Ramucirumab 947687-13-0” NCT05045404 ↗ “Drug: Ramucirumab” NCT03872947 ↗ |
| Known as | 1121B | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743062 ↗ |
| Known as | Cyramza | “healthy volunters receive Cyramza (Ramucirumab) 8mg/kg once” NCT03863587 ↗2“Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]” NCT03686488 ↗ “Ramucirumab (CYRAMZA®)” NCT05071053 ↗ |
| Known as | IMC-1121B | “Ramucirumab (IMC-1121B)” NCT01427933 ↗7“ramucirumab (IMC-1121B)” NCT01515306 ↗ |
| Known as | LY3009806 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743062 ↗ |
| Known as | RAM | “Icrucumab (ICR) and ramucirumab (RAM) bind vascular endothelial growth factor (VEGF) receptors 1 and 2 (VEGFR-1 and -2), respectively.” PMID 28220020 ↗ Feb 20172“Ramucirumab (RAM) is a VEGFR2 monoclonal antibody.” PMID 37268519 ↗ Mar 2023 “ramucirumab (RAM)” NCT07546812 ↗ |
| Action | Inhibit | “Ramucirumab is a human immunoglobulin G1 antibody that binds vascular endothelial growth factor receptor-2 and blocks ligand-stimulated activation.” PMID 25185099 ↗ Sep 2014 |
| Modality | Monoclonal antibody | “a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2” PMID 24930625 ↗ Jun 2014 |
| Route | Intravenous | “administered as an intravenous infusion” NCT00515697 ↗ |
| Target | KDR | “targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.” PMID 25787923 ↗ Mar 2015 |